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Histone deacetylase inhibitors and proteasome inhibitor are all
emerging as new classes of anticancer agents. We chose TSA
and PS-341 to identify whether they have a synergistic efficacy
on human ovarian cancer cells. After incubated with 500 nM
TSA or/and 40 nM PS-341, we found that combined groups
resulted in a striking increase of apoptosis and G2/M blocking
rates, no matter in A2780, cisplatin-sensitive ovarian cancer cell
line OV2008 or its resistant variant C13∗. This demonstrated
that TSA interacted synergistically with PS-341, which raised
the possibility that combined the two drugs may represent a
novel strategy in ovarian cancer.
Keywords: Histone deacetylase inhibitor; Proteasome inhibitor;
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INTRODUCTION
Despite advances in therapy, ovarian cancer remains the most
lethal of the gynaecological cancers. The current standard
therapy for patients with advanced ovarian cancer is cytore-
ductive surgery followed by the administration of systematic
chemotherapy. At least 70% of ovarian cancers will respond to
a combination of platinum- and taxane-based chemotherapy
administered after surgery; unfortunately, the initial response
is not durable and tumors become resistant (1). We ask
whether we can use drugs whose mechanisms of action are
different from those of Cisplatin or Paclitaxel to treat ovarian
cancer.
Histone deacetylase inhibitors (HDACis) are now emerg-
ing as a new class of anticancer agents with potent activity
in a wide spectrum of tumors. They cause the accumulation
of acetylated histones and other proteins regulating chro-
matin structure and transcription, thereby altering the trans-
activation and expression of specific genes that regulate cell
growth arrest, differentiation, or apoptosis (2). Up to now,
at least 12 HDACis are under evaluation in over 100 clinical
trials and have produced encouraging therapeutic responses
with surprisingly good safety profiles (3, 4). Vorinostat, a hi-
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stone deacetylase inhibitor, was recently approved by the US
Food and Drug Administration for treatment of cutaneous T-
cell lymphoma (5). TSA, one of the most extensively studied
HDACis, could inhibit cell proliferation and induced apop-
tosis in ovarian cancer cells in preclinical studies, raising the
possibility that it may have a role to play in ovarian cancer
treatment (6).
Proteasome inhibitors represent a diverse group of agents
that target the 20S proteasome, a component of the ubiquitin-
proteasome complex that is responsible for the degrada-
tion of unwanted cellular proteins (7). PS-341 is a typi-
cally small molecule inhibitor of the ubiquitin-proteasome
pathway. Proteasome plays an essential role in the degra-
dation of most intracellular proteins, including those that
regulate the cell cycle, cell survival and apoptosis, cell
adhesion and trafficking, and transcription factor activa-
tion (8, 9). Furthermore, PS-341 has been reported to al-
ter the levels of p21, p27, Bcl-2, Bax, XIAP, survivin, and
p53, leading to cell cycle arrest and apoptosis in sev-
eral tumor types (10). PS-341 recently received Food and
Drug Administration (FDA) approval for the treatment of
multiple myeloma (11), and it is currently being evaluated for
the treatment of solid tumors, including ovarian cancer (12).
A number of investigators have examined that combined
with HDACis and proteasome inhibitors did exert a syner-
gistic effect in some malignant tumors, such as human mul-
tiple myeloma, non-small cell lung cancer, and head and neck
squamous cell carcinomas (13–15). Such reports showed that
coadministration of HDIs with proteasome inhibitors could
result in a synergistic increase in mitochondrial injury, cas-
pase activation, and apoptosis in association with multiple
perturbations in signal transduction pathways, including in-
activation of NF-κB signaling, downregulation of Bcl-XL,
and disruption of MAP kinase pathway. Because of most
ovarian cancer patients would typically experience resistance
to cytotoxic drugs, whether similar interaction might occur
in ovarian cancer cells has not been reported so far. Here we
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and PS-341 results in a synergistic increase in release of pro-
apoptotic cytochrome c into the cytosol, activation of cas-
pase, and blocking cells in G2/M phase, as well as inhibits
AKT/mTOR pathway. Moreover, similar synergistic interac-
tions occur both in cisplatin-sensitive ovarian cancer cell line
OV2008 and its resistant variant C13∗. Together, these find-
ings suggest that a therapeutic strategy combining TSA and
PS-341 should also be considered in ovarian cancer.
MATERIALS AND METHODS
Cell line and cell culture
A cisplatin-sensitive ovarian cancer cell line (OV2008) and
its resistant variant (C13∗) were gifts from Dr. Rakesh Goel
from the Ottawa Regional Cancer Center, Ottawa, Canada.
A2780 ovarian cancer cell line was obtained from the Amer-
ican Type Culture Collection (Manassas, VA), and cells were
all grown in RPMI 1640 supplemented with 10% FBS (16).
Chemicals and antibodies
Trichostatin A (TSA) was purchased from Sigma-Aldrich
(St. Louis, MO) and the specific proteasome inhibitor PS-
341 was purchased from Millenium Pharmaceuticals (Cam-
bridge, MA). The stock solution for TSA and PS-341 was re-
constituted in dimethyl sulfoxide (DMSO) at a concentration
of 1 mM, stored at −20◦C, and diluted into complete cell
culture medium before use. 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium (MTT), propidium iodide (PI), and
DMSO were purchased from Sigma Chemical Corporation,
USA. Antibodies were obtained from the following commer-
cial sources: anti-XIAP, anti-caspase-3, anti-caspase-9, anti-
cytochrome c, anti-phospho-akt (Ser473), and anti-phospho-
4EBP1 (Thr37/46) were obtained from Cell Signaling
Technology (Beverly, MA); anti-Bax and anti-caspase-8 were
purchased from Newmarkers; and anti-Mcl-1, anti-p21 and
anti-β-actin were obtained from Santa Cruz Biotechnology.
Cell survival assays with MTT
Cells (6 × 103 per well) were grown in 96-well plates for 24 hr
before exposed to different concentrations of the drugs (TSA,
PS-341, alone or combination of the two reagents). Cell pro-
liferation and viability were measured daily for up to 3 con-
secutive days using MTT assay. To each well, 20 ul MTT (5
mg/mL) was added, and the cells were further incubated for
4 hr at 37◦C. Finally, the absorbance of the dye was measured
spectrophotometrically at 570 nm and 630 nm as a reference
wavelength. Each experimental data point represented aver-
age values obtained from four replicates, and each experi-
ment was performed in triplicate.
Flow cytometry
For detecting apoptosis, 1 × 106 cells were washed twice
with phosphate-buffered saline (PBS) and stained with 5
µL AnnexinV-fluorescein isothiocyanate and 10 µL PI (5
µg/mL) in 1 × binding buffer (NanJing Keygen Biotech, Co.,
Ltd.) for 15 min at room temperature in the dark. For de-
tecting cell cycle, cells were harvested and fixed in ice-cold
70% ethanol and stored at −20◦C overnight. Then, these were
washed once in PBS and resuspended in a solution containing
propidium iodide (5 mg/mL) and RNase A (0.5 mg/mL) in
PBS for additional 30 min. Cells were sorted using a FACScan
(BD Biosciences, USA) and analyzed with CellQuest version
3.3 software. The apoptotic cells were calculated after FACS
analysis.
Protein extraction and western blot
Cells were incubated with various agents for the indicated
times. Thereafter, these were washed twice with PBS and
lysed in an ice-cold SDS lysis buffer for 30 min. The lysates
were centrifuged at 12,000 × g at 4◦C for 15 min; the super-
natant was denatured in SDS sapmle buffer at 100◦C for 8 min
and stored at −20◦C. Equal amounts of proteins were sepa-
rated by SDS-PAGE and transferred to nitrocellulose mem-
branes. The membrane was blocked in TBST with 5% non-
fat milk for 1 hr at 37◦C, and then incubated with the various
primary antibodies and secondary antibodies subsequence.
And then visualized with NBT/BCIP/buffer (1:1:500). Pro-
tein loading was assessed by blotting the same membrane
with an antibody against β-actin.
Analysis of cytosolic and mitochondria cytochrome
Cells were lysed in mitochondria lysis buffer [210 mmol/L
mannitol, 70 mmol/L sucrose, 10 mmol/L HEPES (pH 7.4),
1 mmol/L EDTA, and protease inhibitor cocktail] with a
Dounce homogenizer and subjected to centrifugation at
1,000 g to pellet nuclei. Post-nuclear supernatant was cen-
trifuged at 10,000 g to pellet the mitochondria-enriched
heavy membrane fraction, and the resulting supernatant was
further centrifuged to obtain the cytosolic fraction. For im-
munoblot analysis, equal cytosolic and mitochondria extract
amounts of proteins (50 µg) were subjected to 10% SDS-
PAGE. After transferring to nitrocellulose membrane, the
membrane was probed by cytochrome c antibody.
RNA isolation and reverse transcription PCR
To determine p21 mRNA levels induced by drug treatment,
genomic DNA-free total RNA were prepared at indicated
time points from control and drug-treated ovarian can-
cer cells using a TRIzol reagent kit (Invitrogen Life Tech-
nologies). Quantitative PCR was performed using the SYBR
Green Real Time PCR method. Each sample was tested in
triplicate, and relative gene expression was analyzed using the
2−CT method (17), and the results expressed as fold induc-
tion compared with the untreated group. PCR was performed
with a 5′ sense primer (5′- GCC GCG TTT GGA GTG GTA-
3′) and a 3′ antisense primer (5′-GCC GGC GTT TGG AGT
GGT A-3′) for p21. To amplify 18s RNA internal control, a 5′
sense primer (5′-AGT CCC TGC CCT TTG ACA CA-3′) and
a 3′ antisense primer (5′-GAT CCG AGG GCC TCA CTA
AAC-3′) were used.
RNA interference
Annealed, purified, and desalted double-stranded Stealth
siRNA p21 (CUU CGA CUU UGU CAC CGA G) and con-
trol siRNA were ordered from Invitrogen Corporation. Then,
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dish on day 0. On day 1, the cells were transfected with 200
nM siRNA in Opti-MEM medium (GIBICO) without FBS
using Lipofectamine 2000 reagent (Invitrogen). Subsequently
after transfection 24 hr later, cells were dealt with TSA and
PS-341 alone or combination for another 24 hr.
Statistical analysis
The data are presented as means ± SD of at least three sepa-
rate experiments. Comparisons between two groups were an-
alyzed using Student’s t-test. Differences were considered sig-
nificant in all experiments at p < .05.
RESULTS
TSA interacts synergistically with PS-341 to inhibit cell
growth in ovarian cancer cells
To determine the rational combination doses of TSA and
PS-341, we treated cells with various concentrations of TSA
(0 nM, 250 nM, 500 nM, 750 nM, and 1 uM), combined with
the corresponding concentrations of PS-341 (0 nM, 20 nM,
40 nM, 60 nM, and 80 nM) using MTT assay. We then chose
the lowest effective combination concentration of 500 nM
TSA and 40 nM PS-341 to treat the ovarian cancer cells (data
not shown). Then, the cells were exposed to 500 nM TSA with
40 nM PS-341 to determine the time-dependent change in
survival rate for 12, 24, 36, 48, and 60 hr. Treatment of cells
with TSA or PS-341 alone was minimally toxic to the ovarian
cancer cells. Such as in OV2008, a cisplatin-sensitive cell line,
the survival rate was about 73.7 ± 1.5% and 75.0 ± 3.2%, re-
spectively, after treated with 500 nM TSA or 40 nM PS-341
for 48 hr. However, when they were combined, the survival
rate was just about 51.1 ± 2.4% (p < .05). Similar effects
were also detected in other ovarial cancer cell lines, A2780
and the cisplatin-resistant variant C13∗, suggesting that there
is no difference in the synergistic effect no matter whether the
ovarian cancer cell was sensitive to cispltin or not (Figure 1).
TSA interacts synergistically with PS-341 to trigger
apoptosis in ovarian cancer cells
Next, we examined the ability of TSA and PS-341 regimen
to induce apoptosis in these cell lines. Cells were incubated
Figure 1. Enhanced inhibition effect on ovarian cancer cell lines com-
bined with TSA and PS-341. Ovarian cancer cell lines (a) OV2008, (b)
C13∗, and (c) A2780 were incubated with 500 nM TSA or/and 40 nM
PS-341 for the indicated times. At the end of the experiment, the cells
survival rate was assessed with MTT. Every time point the control sur-
vival rate was supposed as 1.0. ∗, p < .05, cells treated with TSA and
PS-341 combination versus TSA or PS-341 alone. Each data point is
the mean ± standard error (SE) of six replicates.
Figure 2. Induction of apoptosis in ovarian cancer cell lines by TSA
and PS-341. Ovarian cancer cell lines OV2008, C13∗, and A2780 were
incubated with 500 nM TSA or/and 40 nM PS-341 for 48 hr. Each
data point represents the mean ± SE apoptosis percentage of three
replicates. ∗, p < .05, cells treated with TSA and PS-341 combination
versus TSA or PS-341 alone.
with drugs alone or combined for 48 h, and then were evalu-
ated by flow cytometry. As shown in Figure 2, at a dose of 500
nM TSA or 40 nM PS-341, only a modest effect on apoptosis
had been observed. However, when the drugs were added to-
gether, the Annexin V positive cells increased obviously in all
three cell lines and the effect of apoptosis is more significant
than single drug treatment (p < .01).
Coadministration of TSA and PS-341 in ovarian cancer cells
resulted in enhanced activation of caspases-3, -8, and -9,
and release of cytochrome c into the cytosolic fraction
Western analysis was subsequently used to assess the ef-
fects of combining TSA and PS-341 on various apoptosis-
associated events in all three cell lines. As shown in Figure
3(a), treatment of cells with TSA, PS-341 alone minimally
triggered cleavage activation of caspases 3, 8, and 9, as well
as release of cytochrome c from mitochondrial into cytoso-
lic. Coexposure of TSA with PS-341 led to obvious increase
in cleaved caspase, and cytosolic release of cytochrome c.
Similar results were obtained in all three cell lines, includ-
ing the cisplatin-resistant variant cell line C13∗. Furthermore,
we performed western blot to detect the changes of anti-
apoptotic proteins and pro-apoptotic proteins (Figure 3b).
Administration of TSA and PS-341 individually or in com-
bination (48 hr) exerted minimal effects on the expression of
Bcl-2, XIAP, Bcl-xl, or Bax. Interestingly, both treatment of
the cells with PS341 alone and coadministration of TSA re-
sulted in an increase in Mcl-1 levels, presumably correspond-
ing to the degradation of Mcl-1 which was blocked by pro-
teasome inhibitors PS341. Thus, these findings indicated that
the synergism of TSA and PS-341 inducing apoptosis might
depend mainly on stimulus mitochondrial injury and caspase
activation, not on changing the expression of Bcl-2 family
members in ovarian cancer cells.
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Figure 3. Effects of TSA and PS-341 on apoptosis-related proteins in
ovarian cancer cells. (a) OV2008, A2780, and C13∗ cells incubated
with 500 nM TSA or/and 40 nM PS-341 for 48 hr. Thereafter, western
analysis was used to assess release of cytochrome into S-100 cytoso-
lic fractions, and total cellular extracts were monitored for expression
of the cleaved fragment of caspases 3, 8, and 9. (b) Western analysis
was also used to assess expression of BCL-2 family members of Bcl-2,
Mcl-1, XIAP, Bcl-XL, and Bax.
TSA interacts synergistically with PS-341 to induce G2/M
arrest in ovarian cancer cells
Previous reports indicated that cell cycle arrest could also be
induced by TSA or PS-341. Flow cytometric analysis showed
that all of the three ovarian cancer cell lines treated with
TSA and PS-341 for 48 hr were obviously arrested at the
G2/M phase, and these effects were much notable than sin-
gle drug treatment (p < .05) (Figure 4a). Such as in A2780,
TSA and PS-341 combination resulted in an obvious in-
crease in the population of cells arrested at G2/M phase
(58.25% vs. 19.56% control, p < .05). Similar results were
also found in the other two cell lines (cisplatin-sensitive
and cisplatin-resistant). Next, we detected several cell cycle
regulatory proteins, such as p21, cyclin B1, Bub1, CDK1,
and MAD2 (Figure 4b). Although some changes were ob-
served in different cell lines, we noticed coincidence accu-
mulation of p21 in three cell lines. The combination also re-
sulted in a marked inhibition in the activity of AKT/mTOR
pathway, as indicated by reduced phosphorylation at AKT
Ser473 and 4EBP1 Thr37/46.
Knockdown of p21 expression enhanced the synergism
effect induced by TSA and PS-341 combination
To determine the biological consequence of p21 upregula-
tion in response to coadministation of TSA and PS-341, we
knocked down p21 expression in cisplatin-resistant variant
C13∗ cells with RNA interference. First, western blot and real
time PCR analysis indicated that the p21 protein and mRNA
expression increased in a time-dependent manner in cells
treated with 500 nM TSA and 40 nM PS-341 at the indi-
cated times (Figure 5a). Next, we designed synthetic siRNA
for silencing p21 expression. Western blot confirmed that p21
Figure 4. Induction of G2/M arrest in ovarian cancer cell lines by TSA
and PS-341. (a) Cells were exposed to 500 nM TSA or/and 40 nM PS-
341 for 48 hr. Cell cycle analysis was performed by flow cytometry.
G2/M phase values represent the mean ± SD of three experiments.
The graphs represent typical results of cell apoptosis. (b) Western anal-
ysis was performed to detect cell cycle related proteins p21, cyclin B1,
Bub1, CDK1, and MAD2, and the level of p-AKT and p-4EBP1.
siRNA sequence effectively suppressed the p21 protein level.
Then, the transfected cells were treated with 500 nM TSA
and 40 nM PS-341 combination for 24 hr, the survival rate
detected by MTT assay was 57.3 ± 2.3% compared with the
negative scrambled siRNA transfected cells 74.5 ± 1.8% (Fig-
ure 5b). At the same time, the flow cytometry analysis on the
apoptosis and cell cycle revealed that 24 hr exposure of p21
siRNA transfected C13∗ cells to 500 nM TSA and 40 nM PS-
341 combination resulted in 28.63 ± 2.1% annexin V posi-
tive cells and 79.04 ± 2.9% G2/M arrest cells, whereas scram-
bled siRNA transfected cells resulted in 19.92 ± 1.6% annexin
V positive cells and 50.53 ± 2.3% G2/M arrest cells (Figure
5c–d). These results indicated that the induced p21 upregu-
lation might play an important role on the TSA and PS-341
combination treatment.
DISCUSSION
Significant advances involving the use of HDACis have re-
ported that some kinds of HDAC inhibitors are active against
ovarian cancer cells (18, 19), suggesting a possible role
for such agents in the therapeutic armamentarium against
this disease. It also has been reported PS-341 had activity
against tumor spheroids, and could trigger obvious apopto-
sis; these studies could be informative with respect to the
use of PS-341 as anticancer agents for ovarian cancer (20,
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Figure 5. Knockdown of p21 expression enhanced the synergism effect
induced by TSA and PS-341. (a) C13∗ cells were treated by 500 nM
TSA combined with 40 nM PS-341 for the indicated times, western
analysis to detect the p21 protein expression (upper panel), and real-
time PCR to detect the p21 mRNA expression (lower panel). Lower
panel, resuls are expressed as fold induction compared with 0 hr group,
and normalized to that of 18s RNA (the 0 hr group being set as 1) (b)
C13∗ cells transfected with p21 siRNA and negative siRNA 24 hr later
were treated with 500 nM TSA and 40 nM PS-341 for 24 hr, cell sur-
vival rate was determined by MTT assays (lower panel). Data represent
the mean of triplicates at each time point. ∗, p < .05, C13∗ cells trans-
fected with p21 siRNA versus those transfected with negative siRNA.
Western blot showed siRNA had the knockdown effect of p21 (upper
panel). (c) C13∗ cells were treated as described for Figure 5(b), cell
apoptosis was analysis by flow cytometry. Apoptotic values represent
the mean ± SD of three experiments. The graphs represent typical re-
sults of cell apoptosis. (d) C13∗ cells were treated as described for Fig-
ure 5(b), cell cycle was analysis by flow cytometry. Here G2/M phase
values represent the mean ± SD of three experiments. The graphs rep-
resent typical results of G2/M arrest.
histone deacetylase inhibitor with proteasome inhibitor PS-
341 might have more potential therapeutic implications in
ovarian cancer.
In this study, we showed that coadministration of HDAC
inhibitor TSA with proteasome inhibitor PS-341 facilitated
apoptosis and cell cycle arrest not only in cisplatin-sensitive
cell line OV2008 but also in cisplatin-resistant variant cell line
C13∗. We also demonstrated that there was no difference in
apoptosis and cell cycle arrest in the three ovarian cancer cell
lines.
The mechanisms involved in the HDAC inhibitor and
proteasome inhibitor are complex and differ among differ-
ent cell types. In our study, we found that the combination of
the two drugs induced mitochondrial permeability transition
with a subsequent release of pro-apoptotic cytochrome c into
the cytosol, resulting in the activation of caspase-9, caspase-
8, and caspase-3, accompanied by minimal changes on the
expression of Bcl-2, XIAP, Bcl-xl, or Bax. These results sug-
gested that TSA and PS-341 combination inducing apopto-
sis might mainly depend on stimulus mitochondrial injury
and caspase activation, which were similar to other studies
(22–24).
To further characterize the growth inhibitory activity of
TSA and PS-341 combination, we performed cell cycle analy-
sis. We observed that cells incubated with the two drugs alone
or combination were all blocked at the G2/M phase, and the
effect was more obvious in combination group than in single-
handed group. Prior investigations revealed that HDACi
mediate G2/M-phase arrest was a much rarer event than
HDACi-induced G1 arrest. And the blocked cells treated with
HDACi eventually moved through the defective checkpoint
and underwent apoptosis, although the underlying mech-
anisms responsible for HDACi-mediated G2/M arrest are
poorly understood (25). Here we observed that TSA and PS-
341 combination could promote p21 accumulation obviously
in all three cell lines. However, other cell cycle regulatory
proteins, such as cyclin B1, Bub1, CDK1, and MAD2, exerted
variable changes in different cell lines. It is well known that
p21 is a negative regulator of cell cycle progression and a
modulator of apoptosis (26, 27). Some studies have shown
that both HDAC inhibitor and proteasome inhibitor could
induce p21 expression (28). To examine the potent meanings
of p21 upregulation, we used RNA interference to knock-
down of p21 expression in C13∗ cells. The p21 siRNA and
negative siRNA transfected cells were treated by 500 nM TSA
and 40 nM PS-341 combination for 24 hr, then MTT analy-
sis revealed that the survival rate of p21 siRNA transfected
cells was much lower than negative siRNA transfected cells.
This suggested that p21 upregulated expression might play
a negative role in the TSA and PS-341 synergism. The
flow cytometry analysis revealed that knockdown of p21
expression enhanced the synergism effects on apoptosis and
G2/M phase arrest. Previous studies have indicated that p21
inhibits apoptosis which might account for its regulation of
gene transcription or inhibition of the activity of proteins,
including procaspase 3, caspase 8, caspase 10 (29, 30).
Paradoxically, p21 might also promote apoptosis depending
on both p53-dependent and p53-independent upregulation
of the pro-apoptotic protein BAX (31). Exactly how induced
p21 upregulation inhibited apoptosis and cell cycle arrest
needs further investigation. In addition, combined treatment
with TSA and PS-341 also resulted in marked inhibition in
the activity of AKT/mTOR pathway, which played a pivotal
role in the genesis of diseases including cancer.
In summary, our study provided evidence that the TSA
combined with PS-341 potently inhibited the growth of hu-
man ovarian cancer cells by inducing apoptosis, accumula-
tion of cells in G2-M phase. Our results regarding the syner-
gistic efficacy of TSA and PS-341 may open new and interest-
ing perspectives in the therapeutic strategy for the treatment
of human ovarian cancer.
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